Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TBI-2001 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on TBI-2001, a putative cell therapy comprising T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TBI-2001 | TBI 2001|TBI2001 | CD19 Immune Cell Therapy 73 | Limited information is currently available on TBI-2001, a putative cell therapy comprising T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |